Back to Search
Start Over
Bevacizumab-containing treatment for relapsed or refractory Wilms tumor.
- Source :
-
Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 Sep; Vol. 24 (9), pp. 837-843. Date of Electronic Publication: 2024 Jul 23. - Publication Year :
- 2024
-
Abstract
- Introduction: Angiogenesis is critical for tumor growth and metastasis. Bevacizumab is an antiangiogenic drug used to treat various adult and childhood solid tumors. Its potential efficacy in Wilms tumor (WT) with poor prognosis is not established.<br />Areas Covered: The response to bevacizumab-containing regimens in relapsed or refractory WT was reviewed in available literature. Searches were conducted using PubMed, Scopus, and ClinicalTrials.gov databases. Eight papers were identified, published between 2007 and 2020, including six treatment regimens, predominantly vincristine, irinotecan, and bevacizumab (VIB) ± temozolomide (VITB). Among 16 evaluable patients, there were two complete responses, seven partial responses, five patients achieved stable disease (SD), and two patients had progressive disease. Objective responses (OR) were observed in 56% of all cases. OR or SD was observed in 89% (8/9) patients who received VIB/VITB. Bevacizumab was generally well tolerated. Related toxicities included hypertension, proteinuria, and delayed wound healing.<br />Expert Opinion: This review suggests potential effectiveness and good tolerability of bevacizumab in the setting of relapsed/refractory WT when used in combination with other drugs. Such combination therapies may serve as a bridging treatment option to other interventions and more personalized treatment options in the future; however, focused trials are needed to obtain additional evidence.
- Subjects :
- Humans
Child
Prognosis
Neovascularization, Pathologic drug therapy
Neovascularization, Pathologic pathology
Bevacizumab administration & dosage
Bevacizumab adverse effects
Bevacizumab pharmacology
Wilms Tumor drug therapy
Wilms Tumor pathology
Kidney Neoplasms drug therapy
Kidney Neoplasms pathology
Angiogenesis Inhibitors administration & dosage
Angiogenesis Inhibitors adverse effects
Angiogenesis Inhibitors pharmacology
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Antineoplastic Combined Chemotherapy Protocols adverse effects
Antineoplastic Combined Chemotherapy Protocols pharmacology
Neoplasm Recurrence, Local drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1744-8328
- Volume :
- 24
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Expert review of anticancer therapy
- Publication Type :
- Academic Journal
- Accession number :
- 39016020
- Full Text :
- https://doi.org/10.1080/14737140.2024.2381537